Background Image
Previous Page  153 / 156 Next Page
Information
Show Menu
Previous Page 153 / 156 Next Page
Page Background

151

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

345

Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidow J, Pierce A, Morten-

sen E,Kleoudis C, Carter E. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR)

antagonist for the treatment of opioid-induced bowel dysfunction: results from a rando-

mized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for

chronic non-cancer pain. Pain 2008; 137(2): 428-440.

346

Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough

pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety

study. Cancer 2009; 115(11): 2571-2579.

347

Wells N, Murphy B, Douglas S, Yelton N. Establishing the safety and efficacy of an opioid

titration protocol. J Opioid Manag 2005; 1(1): 41-48.

348

Wirz S, Wartenberg HC, Elsen C, Wittmann M, Diederichs M, Nadstawek J. Managing can-

cer pain and symptoms of outpatients by rotation to sustained-release hydromorphone:

a prospective clinical trial. Clin J Pain 2006; 22(9): 770-775.

349

Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing

hydromorphone and morphine? A prospective open-labeled investigation on cancer pain.

Support Care Cancer 2008; 16(9): 999-1009.

350

Wirz S,Wittmann M,Schenk M,Schroeck A,Schaefer N,Mueller M,Standop J,Kloecker

N,Nadstawek J. Gastrointestinal symptoms under opioid therapy: a prospective compa-

rison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal

buprenorphine. Eur J Pain 2009; 13(7): 737-743.

351

Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases.

Cochrane Database of Systematic Reviews 2009; (4).

352

Wong RH, Lee TW, Sihoe AD, Wan IY, Ng CS, Chan SK, Wong WW, Liang YM, Yim AP. An-

algesic effect of electroacupuncture in postthoracotomy pain: a prospective randomized

trial. Ann Thorac Surg 2006; 81(6): 2031-2036.

353

Wu N, Yan S, Wang X, Lv C, Wang J, Zheng Q, Feng Y, Yang Y. A prospective, single-blind

randomised study on the effect of intercostal nerve protection on early post-thoracotomy

pain relief. Eur J Cardiothorac Surg 2010; 37(4): 840-845.

354

Wu YQ, Li H, Xiong JC, Xu ZM, Ma LY, Huang XM, Zhang DT, Feng J. [Effects of patient-con-

trolled analgesia with small dose ketamine combined with morphine and the influence

thereof on plasma beta-endorphin level in patients after radical operation for esophageal

carcinoma]. Zhonghua Yi Xue Za Zhi 2009; 89(5): 314-317.

355

Xu JM, Song ST, Feng FY et al. Cobrotoxin-containing analgesic compound to treat chronic

moderate to severe cancer pain: results from a randomized, double-blind, cross-over

study and from an open-label study. Oncol Rep 2006; 16(5): 1077-1084.

356

Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pan-

creatic cancer. Am J Gastroenterol 2007; 102(2): 430-438.

357

Yang Q, Xie DR, Jiang ZM, Ma W, Zhang YD, Bi ZF, Chen DL. Efficacy and adverse effects of

transdermal fentanyl and sustained-release oral morphine in treating moderate-severe

cancer pain in Chinese population: a systematic review and meta-analysis. J Exp Clin

Cancer Res 2010; 29: 67.

Literaturverzeichnis